ScholarWorks@Gachon: Lee, Jae Hoon

Detailed Information

Lee, Jae Hoon (이재훈)

College of Medicine (Department of Medicine)

Research Area

Tel 032-458-2858
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Multiple myeloma:18||multiple myeloma:12||Prognosis:11||Chemotherapy:9||Rituximab:7||Bortezomib:7||Survival:6||diffuse large Bcell lymphoma:5||Myeloma:5||Acute myeloid leukemia:5||Lymphoma:5||prognosis:5||NonHodgkin lymphoma:4||Elderly:4||Cyclophosphamide:4||Oxaliplatin:3||Diffuse large Bcell lymphoma:3||Melphalan:3||Bone marrow:3||Busulfan:3||Gastric cancer:3||Lenalidomide:3||Response:3||Etoposide:2||lenalidomide:2||Cytarabine:2||myeloma:2||nasal type:2||CLL:2||Paroxysmal nocturnal hemoglobinuria:2||Daratumumab:2||autologous stem cell transplantation:2||azacitidine:2||Eculizumab:2||bortezomib:2||Cisplatin:2||panobinostat:2||Korea:2||chronic lymphocytic leukemia:2||phase 3:2||Secondline:2||Autologous transplantation:2||Stem cell transplantation:2||decitabine:2||s lymphoma:2||Consolidation:2||Pyrosequencing:2||Aplastic anemia:2||Nonsmall cell lung carcinoma:2||survival:2||thalidomide:2||Radiotherapy:2||treatment:2||EGFR:1||EGFR TKI:1||Early Response:1||East Asian:1||Effectiveness:1||Efficacy and safety:1||Elderly AML:1||Elderly multiple myeloma:1||Epidemiology:1||Epidermal growth factor receptor:1||Epirubicin:1||Ethnicity:1||Exon 20:1||Extranodal NK/T cell lymphoma:1||Extranodal NK/Tcell lymphoma:1||FDGPET/CT:1||Far East:1||Ferritin:1||Finger:1||Flexor digitorum profundus:1||Fragment analysis:1||Frailty:1||Gefitinib:1||Gemcitabine:1||Geriatric assessment:1||Glucocorticoids:1||Guideline:1||HER2:1||Hematocrit:1||Hematopoietic stem cell transplantation:1||Hepatitis B:1||Hepatitis B Core Antigen:1||Hepcidin:1||Highrisk cytogenetics:1||Histone deacetylase inhibitor:1||Hodgkin&apos:1||ISS:1||Idarubicin:1||Immune hemolytic anemia:1||Immune thrombocytopenia:1||Immunohistochemistry:1||Immunostaining:1||Induction:1||Induction chemotherapy:1||Infection:1||Inflammatory markers:1||Infusionrelated reaction:1||Intratendinous fibroma:1||Intravenous busulfan:1||Irinotecan:1||IsaPd:1||Ixazomib:1||Japan:1||KRAS mutation:1||Key words Autologous stem cell transplantation:1||Ki67:1||Korean:1||LAsparaginase:1||Lasparaginase:1||Lactate dehydrogenase:1||Latin America and Asia:1||Lenalidomide and dexamethasone:1||Lenalidomide plus dexamethasone:1||Leukemia:1||LongTerm Outcome:1||Lymphocytes:1||MALT lymphoma:1||Magnetic resonance imaging:1||Maintenance:1||Marginal zone:1||Marginal zone lymphoma:1||Metabolic tumor volume:1||Methylprednisolone:1||Multicenter:1||Multiple Myeloma:1||Myelodysplastic syndrome:1||Nras:1||Neoplasm staging:1||Neutropenia:1||Neutrophils:1||Nilotinib:1||NonHodgkin?s lymphoma:1||Nonsmall cell lung cancer:1||Older adults:1||Open label:1||Overall Survival:1||PLR:1||POEMS Syndrome:1||PTG300:1||PV:1||Pancreatic neoplasms:1||Paroxysmal Nocturnal Hemoglobinuria:1||Pemetrexed:1||Pharmacokinetics:1||Philadelphia chromosome positive:1||Plasma exchange:1||Plasmacytoma:1||Platinum:1||Polycythemia Vera:1||Population study:1||Positronemission tomography:1||Postmarketing surveillance:1||Postpolycythemia vera myelofibrosis (postPV MF):1||Predictive factor:1||Prognostic factors:1||Pseudolymphoma:1||Purpura:1||R CHOP:1||RCVP:1||RRMM:1||RealWorld Evidence:1||Realworld evidence:1||Receptor, epidermal growth factor:1||Refractory:1||Relapsed:1||Relapsed and:1||Relapsed and refractory:1||Relapsed myeloma:1||Renal insufficiency:1||Resection:1||Responseadapted therapy:1||Rusfertide:1||S1:1||Sanger sequencing:1||Sarcopenia:1||Screening PCR:1||Selinexor:1||Small cell lung carcinoma:1||Splenectomy:1||Stem cell:1||Stem cell mobilization:1||Stomach cancer:1||Survival analysis:1||Thalidomide:1||Therapeutic Phlebotomy:1||Thrombotic microangiopathies:1||Thrombotic thrombocytopenic:1||Toxicity:1||Transplantineligible:1||Transplantation:1||Trastuzumab:1||Tretinoin:1||Tumor burden:1||Tyrosine kinase inhibitor:1||Unroofing technique:1||VMP:1||Vincristine:1||acalabrutinib:1||acute:1||acute lymphoblastic leukemia:1||acute myeloid leukemia:1||aged:1||autoSCT:1||biomarkers:1||bone marrow involvement:1||breast:1||central nervous system:1||chemotherapy:1||clonality:1||combination:1||comparison:1||concurrent chemoradiotherapy:1||conditioning:1||conditioning regimen:1||consolidation:1||cord blood transplantation:1||cyclophosphamide:1||cytogenetics:1||deacetylase inhibitor:1||discontinuation:1||dose intensity:1||drug therapy:1||epsteinbarr virus:1||extranodal NK/Tcell lymphoma:1||febrile neutropenia:1||granulocytecolony stimulating factor:1||hematopoietic stemcell transplantation:1||immunomodulatory drug:1||international prognostic index:1||medical imaging:1||melphalan:1||methotrexate:1||myelodysplastic syndrome:1||myelodysplastic syndromes:1||natural history:1||newly diagnosed:1||nonHodgkin&apos:1||nonhodgkin lymphoma:1||nonsmall cell lung cancer:1||novel agents:1||novel therapy:1||nuclear diameter:1||older adults:1||or refractory multiple myeloma:1||overall survival:1||p53:1||pegfilgrastim:1||peripheral neuropathy:1||pomalidomide:1||primary plasma cell leukemia:1||prognostic:1||promyelocytic:1||prophylaxis:1||proteasome inhibitor:1||q11.2):1||refractory:1||relapse:1||relapsed:1||relapsed or relapsed and refractory:1||resourcestratified:1||responseadapted therapy:1||ricolinostat:1||rituximab:1||safety:1||salvage therapy:1||stem cell mobilization:1||surveillance:1||t(11:1||transplantineligible:1||글루코코르티코이드:1||급성 골수성 백혈병:1||리툭시맙:1||림프종:1||무형성빈혈:1||조혈모세포이식:1||항암제:1||항암화학요법:1||핵심항원:1||혈장교환술:1||혈전성혈소판감소자반증:1||혈전혈관병증:1||14)(p13:1||호중구 감소증:1||18 FFDG PET/CT:1||AML:1||Advanced stage:1||Alkylating agent:1||Anemia:1||Antibiotic prophylaxis:1||Asia:1||Asian population:1||Autologous:1||Autologous Stem Cell Transplantation:1||Autologous stem cell transplantation:1||BIOMED2:1||BTK inhibitors:1||Bacterial infection:1||Belotecan:1||Bendamustine:1||Bloodstream infection:1||Bone lymphoma:1||Bone marrow involvement:1||Brain metastases:1||Burkitt lymphoma:1||B형 간염:1||Creactive protein:1||CALR:1||CD20:1||CD30:1||CD38:1||CD99:1||CVAD protocol:1||CVD:1||Capecitabine:1||Carcinoma, nonsmallcell lung:1||Carfilzomib:1||Chop14:1||Chromosomal abnormalities:1||Chronic myeloid leukemia:1||Clinical trials:1||Complement C5 inhibitor:1||Corticosteroids:1||CrELfree paclitaxel:1||Cytogenetic Analysis:1||Cytogenetics:1||Dapsone therapy:1||Dexamethasone:1||Diagnosis:1||Diffuse large B cell lymphoma:1||Diffuse large B cell lymphoma:1||Diffuse large bcell lymphoma:1||Diffuse large cell lymphoma:1||Direct sequencing:1||Docetaxel:1||Drug therapy:1||

RSS_1.0 RSS_2.0 ATOM_1.0

1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE